Resources Repository
-
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Health/Medicine | Business/Industry | North America | Chronic Disease/Risk | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Mental Health | Health Systems | Economics/Finance | Government/Law | Science/Technology | Europe -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Benefit-Cost Analysis | Health/Medicine | North America | Chronic Disease/Risk | Preferences/Values | Costing Methods | Mental Health | Policy/Regulation | Economics/Finance | Government/Law -
ArticlePublication 2015Valuing Regulations Affecting Addictive or Habitual Goods
The analysis of regulations affecting addictive or habitual goods has drawn considerable controversy. Some studies …
The analysis of regulations affecting addictive or habitual goods has drawn considerable controversy. Some studies have suggested that such regulations have only small welfare benefits, as consumers value these goods despite health benefits from quitting, while other studies suggest that information or behavioral problems make existing consumption decisions a poor guide to welfare evaluation. This analysis examines potential utility offsets to health benefits of regulations affecting addictive or habitual goods theoretically and empirically. The paper…
Benefit-Cost Analysis | Health/Medicine | North America | Chronic Disease/Risk | Preferences/Values | Social Determinants | Policy/Regulation | Culture/Society | Economics/Finance -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Health/Medicine | Business/Industry | North America | Chronic Disease/Risk | Preferences/Values | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Mental Health | Health Systems | Policy/Regulation | Government/Law | Science/Technology -
BookPublication 1980Clinical Decision Analysis
This text was conceived and developed in the Harvard T.H. Chan School of Public Health …
This text was conceived and developed in the Harvard T.H. Chan School of Public Health at the Center for the Analysis of Health Practices. The book had its origins in a set of classroom materials developed during the academic year 1974-75 for an elective course in medical decision making at the Harvard Medical School. In this book students are shown how to structure clinical decision problems, how to systematically formulate the intertwining roles of diagnosis and treatment, how to…
Health/Medicine | North America | Chronic Disease/Risk | Probability/Bayes | Preferences/Values | Costing Methods | Health Outcomes | Test Performance | Value of Information | State-Transition | Decision Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Economics/Finance | Global | Europe | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
Resource PackWeb Portal, Teaching Resource 2023Resource Pack: Cost-Effectiveness of Screening and Treatment for Hypertension
Hypertension is a relevant example for teaching clinical decision making, diagnostic test performance, positivity criterion, …
Hypertension is a relevant example for teaching clinical decision making, diagnostic test performance, positivity criterion, and cost-effectiveness analysis. This resource pack provides examples of decision analyses and cost-effectiveness analyses for the management and treatment of hypertension, with a predominant focus on the U.S. Analyses are included that predate the 2017 American College of Cardiology/American Heart Association Clinical Practice Guidelines, along with more recent examples that followed release of the guidelines. Resources are also included that…
Health/Medicine | North America | Chronic Disease/Risk | Preferences/Values | Test Performance | Decision Analysis | Cost-Effectiveness Analysis | Clinical Care | Economics/Finance | Science/Technology | Europe | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
Online LearningVideo, Teaching Resource 2017Forum. The Opioid Crisis: A Governors Roundtable
Opioid overdoses claim the lives of 91 Americans every day, according to the Centers for …
Opioid overdoses claim the lives of 91 Americans every day, according to the Centers for Disease Control and Prevention. This Forum - The Opioid Crisis: A Governors Roundtable, is part of the series, Policy Controversies, and was presented jointly with PRI’s The World & WGBH News. In this multimedia forum, four former governors offered candid insights into how government policy can help, exploring what works and what doesn’t. They spoke about experiences within their own…
Health/Medicine | North America | Chronic Disease/Risk | Priority Setting/Ethics | Health Outcomes | Mental Health | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Health/Medicine | North America | Chronic Disease/Risk | Preferences/Values | Health Outcomes | Decision Analysis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Europe -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Benefit-Cost Analysis | Health/Medicine | North America | Chronic Disease/Risk | Costing Methods | Policy/Regulation | Government/Law